US equities
|
NVDA
$239.79
▲+2.50%
SPCX
$169.50
▲+6.63%
MU
$1,060.30
▼-1.36%
TSLA
$380.82
▲+2.76%
SNDK
$1,692.10
▼-1.62%
MSFT
$528.49
▲+2.12%
INTC
$116.41
▼-2.45%
META
$743.69
▲+2.14%
NVDA
$239.79
▲+2.50%
SPCX
$169.50
▲+6.63%
MU
$1,060.30
▼-1.36%
TSLA
$380.82
▲+2.76%
SNDK
$1,692.10
▼-1.62%
MSFT
$528.49
▲+2.12%
INTC
$116.41
▼-2.45%
META
$743.69
▲+2.14%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.020
+0.140 (+4.86%)
Delayed Quote
Updated: 3:04 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients
December 27, 2021
Via
Investor Brand Network
Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
↗
December 23, 2021
In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
December 23, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD
December 22, 2021
Via
Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM)
December 22, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
December 21, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
December 21, 2021
Via
Investor Brand Network
Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
↗
December 17, 2021
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood...
Via
Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
December 17, 2021
Via
Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
December 17, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension
December 17, 2021
Via
Investor Brand Network
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
Kelowna, British Columbia – TheNewswire - December 16, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms...
Via
TheNewswire.com
Lexaria Bioscience Committed to Innovation and Improving Quality of Life
↗
December 15, 2021
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Committed to Innovation and Improving Quality of Life
December 15, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
December 14, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
December 14, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
December 14, 2021
Via
CannabisNewsWire
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human...
From
Lexaria Bioscience Corp.
Via
AccessWire
Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B
↗
December 13, 2021
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s...
Via
Benzinga
Lexaria’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Exceeding $160B
December 13, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion
December 10, 2021
Via
Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 10, 2021
Gainers Reshape Lifesciences (NASDAQ:RSLS...
Via
Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
December 08, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
December 08, 2021
Via
Investor Brand Network
52 Biggest Movers From Yesterday
↗
December 09, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to...
Via
Benzinga
Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference
↗
December 08, 2021
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of...
Via
Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
↗
December 08, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
December 08, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
December 08, 2021
Via
Investor Brand Network
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
